

FIG. 1

FIG. 2







FIG. 3A

304- <b>G</b> \	
Expression statistic for gene <b>G</b> from organism 1	308- <b>G</b> -1
Expression statistic for gene <b>G</b> from organism 2	308- <b>G</b> -2
Expression statistic for gene <b>G</b> from organism 3	308- <b>G</b> -3
Expression statistic for gene G from organism 4	308- <b>G</b> -4
•	333 🗸 ,
Expression statistic for gene <b>G</b> from organism N	308 <b>-G</b> -N







**FIG. 4** 



**FIG. 5** 



8/91



<sub>9/91</sub>FIG. 7




FIG. 8




FIG. 9






FIG. 10





(PRIOR ART) FIG. 11



nicotinamide nucleotide transhydrogenase



9530010C24Rik



ectonucleotide pyrophosphatase



EST AW456442



5' nucleotidase



EST AW540195



purine-nucleosi de phosphorylase



N-terminal Asn amidase



nicotinami de Nmethyltransferase



aldehyde oxidase 1

(PRIOR ART) FIG. 12




FIG. 13





FIG. 14



17/91




FIG. 16







FIG. 17





**FIG. 19** 



**FIG. 20** 

	95
Phenotypic Statistic Set for Cli	inical Trait 1 2102-1
Phenotypic value for Org	anism 1 2104-1-1
Phenotypic value for Org	anism 2 2104-1-2
Phenotypic value for Org	anism 3 2104-1-3
Phenotypic value for Org	anism Q 2104-1-Q
•	
Phenotypic Statistic Set for Cli	inical Trait Z 2102-Z
Phenotypic value for Org	anism 1 2104-Z-1
Phenotypic value for Org	anism 2 2104-Z-2
Phenotypic value for Org	anism 3 2104-Z-3
•	
Phenotypic value for Org	anism Q 2104-Z-Q

FIG. 21

$\sim$ 20	
Expression quantitative trait loci (eQTL) identification module	$\nearrow$
Clinical quantitative trait loci (cQTL) identification module	$\nearrow$
Determination module	$\nearrow$
•	1
•	İ

FIG. 22




FIG. 23






FIG. 24

Select a genes from reference species (e.g., a mouse gene) that was identified using quantitative genetics methods (e.g., a gene verified in processing step 222 of Fig. 2 or a gene that has been associated with clinical trait T in processing step 1920 of Fig. 19)





BLAST search of all known nucleotide sequences in target species using the nucleotide sequence of gene G to obtain best match G'

BLAST search of protein sequences in target species using the translated amino acid sequence for gene G, denoted P, to obtain best match P'



BLAST search of nucleotide sequences in reference species with G'






Ortholog to gene G in the target species has been identified

**FIG. 25** 

2508

2514



**FIG. 26** 




Figure 27

GTGGGACCCGCTGCTGATCCTGTCGCAGATCGTCCTCATGCAGACCGTGTATTACGGCTCGCTGGGCCTG TGGCTGGCGCTGGTGGACGGCCTAGTGCGACAGCCCCTCGCTGGACCAGATGTTCGACGCCGAGATCCTG GGCTTTTCCACCCCTCCAGGCCGGCTCTCCATGATGTCCTTCATCCTCAACGCCCTCACCTGTGCCCTGG  ${\tt GCTTGCTGTACTTCATCCGGCGAGGAAAGCAGTGTCTGGATTTCACTGTCACTGTCACTTTCATCTCACCTT}$ CAGCCCCTAAATCCAATGTCTAGAATCAGGCCCTTTGGACATCCTGCTGACACTTGGGCCCCTTAACACC TTGGGCTGCTCAGACCCTCCAGATGAGGTCCAGCCCAGATCTGAGAGGAACCCTGGAAATGTGAAGTCTC TGTTGGTTTGGGAGAGATAGTGAGGGCCTGTCAAAGAAGGCAGGTAGCAGTCAGCATGACAGCTGCAAGA ATGACCTCTGTCTGTTGAAGCCTTGGTATCTGAGAGGTCAGGAAGGGGACCTCTTTGAGGGTAATAACAG  ${\tt CAAGGATATCTGATTGGAGCAAACCACTTCTTTAGTCATCTGTCTTACCCCCCTGGGACAGCTGTTACCT}$ TTGCAGTGTTGCCGAATCACAGCAGTTACCTTTGCAGTGTTGCCGAATCACAGCAGTTCTGTTGGAGAAA CGCTTGGTTTCCGGATCCAGAGCCACAGAAAGAAATGTAGGTGTGAAGTATTAGGCTGCTGTCAGGGAGA GGATGGCAGATGGAGGCATCAAGCACAAGGAAAATGCACAACCTGTGCCCTGTTATACACACGTTCATGT GCACCCAAGAACCTATGACTTTCTTCCAGTTCCTTCTACCAGGTCCCCATCCTGCTGCCAGCTCTCAACA TAGCAGGCCATAGGACCCAGAGAAGAATCCCAGCGTTGCTCAAAGTCTAACCATCATAAAGACACTGCCT  $\tt CTTTGGCGGGAAGGGTATGATGGGTTCCCAGAGACAAGAAGCCCAACCTTCTGGCCTGGGCTGTGCTGAT$ AGTGCTGAGGGAGATAGGAATTTGCTGCTAAGATTTTTCTTTGGGGTGGAGTTTCCTCTGTGAGGGGCTT ACGGTTGAGATTGAGAGAGATCAGCGCAGCCAGGCAAGGGAACTTTAAAGAATTATTAGGCCACCTTCTC CCTTTCCTGGACCCCAGAGTCATTCCTCCATTTGGTTAAAATACTCAGTGCAGGGAACTCTTACATCCTG TCTCCTTCACTTGCAGCGTCCCCTGCTATGCCTCAGGTGAACCACATAATTCTTGGGTTTCCGTTCCTAC TTGCTAGTGATTTCTGAACATGTTCAATGGAGCGGCACACAGTCTAGACCCACTTCCGCATTGAAACCTT  ${\tt CACTGTTCCTCTTGGTTTCTTCAGAGCTTTTCCCAAGAGAGCTGTCAGTTTTCAGCTGTCAGTAACACAA}$  ${ t ATGAGTTTATGGTAACACAAATGAGTTTTGCTATCTCTCTGAGAAGCTCATCTGACCTCCTGACTCTCAG$ ATGAGGCACAGTAATCCTGGCTGCAGGGTCTAGGAGGTAAGACCAGCTGGGATGACCTTCCCTGGGTTAA TCAATTTCCCTCTAGACAACACAAACTGCAGGCATGTGACTAACTTTGAAAGAACACCCATCATGTGGCT GCTGTCACCCTTGACCAGCCGTGGTGGTTGCTTACTCCATCTGTGGTTGGAGCGCCTCTTTGGGATTCACT TCAAGGTCTTGTGCCTATTTTTCTGCATATCTTCTGTGATGACAAATCTCTGTCCCCTGAGTGTTAATTT GATTTTTAGAAATGGCCAAAAGTCACGTGATCCAAACTTTTTTTCAGTAATATGGAGACTGAGCTGCATG GTAGTTGGGGATCAAAAATATGTGACCTTAATGAGATTTTTATGATTTCTAAAGTAACAATAAAAGCAGT ATCTATTGAGTGCTTAA

Figure 28

ATGGCGGGTCAGTTCCGCAGCTACGTGTGGGACCCGCTGCTGATCCTGTCGCAGATCGTCCTCATGCAGA
CCGTGTATTACGGCTCGCTGGGCCTGTGGCTGGCGCTGGTGGACGGCCTAGTGCACAGCCCCTCGCTGG
ACCAGATGTTCGACGCCGAGATCCTGGGCTTTTCCACCCCTCCAGGCCGGCTCTCCATGATGTCCTTCAT
CCTCAACGCCCTCACCTGTGCCCTGGGCTTGCTGTACTTCATCCGGCGAGAAAGCAGTGTCTGGATTTC
ACTGTCACTGTCCATTTCTTTCACCTCCTGGGCTGGTTCTACAGCTCCCGTTTCCCCTCGGCGCTGA
CCTGGTGGCTGGTCCAAGCCGTGTGCATTGCACTCATGGCTGTCATCGGGGAGTACCTGTGCATGCGGAC
GGAGCTCAAGGAGATACCCCTCAACTCAGCCCC

## Figure 29

MAGQFRSYVW	DPLLILSQIV	LMQTVYYGSL	GLWLALVDAL	VRSSPSLDQM	TDARTLGEST
PPGRLSMMSF	VLNALTCALG	LLYFIRRGKO	CLDFTVTVHF	FHLLGCWLYS	SPRDSALTWW
LVQAVCIALM	AVIGEYLCMR	TELKEIPLSS	APKSNV		DICTION

## Figure 30A

## Figure 30B

MAGQFRSYVW	DPLLILSQIV	LMQTVYYGSL	GLWLALVDAL	VRKPVPGPDV	PRCDPCT.T.HD
SRPALNDVLR	PQRPHLCPGL	AVLHPAREAV	PGFHCHCAFL	SPPGLLATIOL	DEDI'GVDI'AV
GPGCVHCTHG	RHRGVPVHAD	GAOGDPPOLS	P	2-1022.002	TITIOADIVA

#### Figure 30C

MAGQFRSYVW	DPLLILSQIV	LMQTVYYGSL	GLWLALVDAL	VRSSPSLDOM	FDAEILGFST
PPGRLSMMSF	VLNALTCALG	LLYFIRRGKQ	CLDFTVTVHF	FHLLGCWLYS	SRFPSALTWW
LVQAVCIALM					

## Figure 30D

PFPGSRGPQL	FGLSRPAGPP	LHGPVCQRCV	RRPVPRSGRA	PTLRPSSRSR	VSRRPRDDGV
VALTGAGGCR	APRAGMAGQF	RSYVWDPLLI	LSQIVLMQTV	YYGSLGLWWR	WWTRWCAODV
PGPDVRRGDP	GLLHPSRPAL	NDVLRPQRPH	LCPGLAVLHP	AREAVPGFHC	HCAFLSPPGL
LALQLPFPLG	ADLVAGPGCV	HCTHGRHRGV	PVHADGAQGD	PPQLSP	

# Figure 30E

MAGQFRSYVW SRPALNDVLR	DPLLILSQIV PORPHLCPGL	LMQTVYYGSL AVIHPAREAU	GLWLALVDAL	VRKPVPGPDV	RRGDPGLLHP PFPLGADLVA
GPGCVHCTHG	RHRGVPVHAD	GAOGDPPOLS	P	SEEGDIWIÓU	PEPLGADLIVA

# Figure 30F

Magqfrsyvw	DPLLILSQIV	LMQTVYYGSL	GLWLALVDGL	VRQPLAGDPV	RRRDPGLFHP
SRPALHDVLH	PQRPHLCPGL	AVLHPARKAV	SGFHCHCPFL	SPPGLLVLOL	PFPLGADLVA
GPSRVHCTHG	CHRGVPVHAD	GAOGDTPOLS	P		

Figure 31




Figure 32A

2821	TCCGTTCCTC	TCTACCAAGG	CTTCCTGATC	ATTGGGTATT	רייות ריכית ייבורית	G3 GG3 EGE===	
2881	CCCGTGTTCT	CCCTGGTTTT	GGACAAAGAC	GTGAAGTCGG			
2941	GAGCTCTACA	AGGACCTGCT		CCACTGTCCT		GTTGTATCCT	
3001		GCATCTATCA		ATCATGTACG		CTTAATTTGG	
3061						GCTGTTCGAG	
3121	ATGGTGGCGC	THURCHUMICAN	GGCAATCTCC	TTCACATCCC	TCATCCTCAC	TGAGCTACTG	
3181	ATGGTGGCGC	1CACCA1CCA	GACGTGGCAC	TGGCTCATGA	CAGTGGCCGA	GCTACTCAGC	
3241	CIGGCCIGCI	ACATTGCCTC	CCTGGTGTTC	CTCCATGAGT	TCATCGATGT	CTACTTCATT	
	GCCACCCIGI	CATTCCTCTG	GAAGGTGTCC	GTCATCACCT	TGGTCAGCTG	TCTCCCCCTC	
3301	TITTOTCCTCM	AGTACCTGCG	GAGACGGTTC	TCCCCACCCA	GCTACTCGAA	GCTCACTTCC	
3361		GGCTGCCTCG	GGCAGGGCCT	CCGGCCTCCG	GCGCTNTCCC	CACCACATCC	
3421	TCAAGTTCCA	CACGCACGAG	CCGCCTCTGC	TGGACGGTGC			
3481	GCTTCGCTGA	GGCGACACTG					
3541				44444	CATTGGTGGA	ACCGGAGGGA	
3601				CCCCTAA	GCTGTGCTGA	GGGGGAAGAC	
3661			TGAGGTTTGT	GGGTCACTG	TGCAAGCTTC	CCTTATGGTT	

Figure 32B

yene with protein product, function

LocusID Org Symbol Description  Li1981 Mm Atp9a ATPase, class II, type 9A  More Mm ATPase, class 2; ATPase 9A, p type; Class II; ATPase 9A,	Symbol and Mame (MGI)	Atp9a: ATPase, class II, type 9A	LocusID: 11981	Overview	Locus Type: gene with protein pr	known or inferred	Product: ATPase, class 2	41	Symbols:	Alias: Class II		-	Function	Gene Ontology™;	Term	• membrane
											rg Symbol Description	m Atp9a ATPase, class II, type	V6	Mm ATPase, class 2;	ATPase 9A, p type;	Class II; ATPase 9A,

Gene Ontologym;		
Térm	Eviden	Evidence Source Pub
• membrane	IEA	MGD
<ul> <li>hydrolase</li> </ul>	IEA	MGD
<ul> <li>metabolism</li> </ul>	IEA	MGD
ATP binding.	IEA	MGD
<ul> <li>cation transport</li> </ul>	IEA	MGD
<ul> <li>magnesium binding</li> </ul>	IEA	MGD
<ul> <li>integral membrane protein</li> </ul>	IEA	MGD
<ul> <li>plásma membrane cation- transporting ATPase</li> </ul>	IEA	MGD

	20q13.11-13.2 ATP9A Hs	20q13.11-13.2 ATP9A Hs
Relationships Annual Human Homology Maps:	NCBI vs. MGD	UCSC vs. MGD

Category: NCBI Genome Annotation Sequences (RefSeq)

NT 011362 Genomic

Contig:

gb sv mv ev mm

Annotated transcripts/proteins for this locus:

Evidence:

supported by alignment with both mRNA and ESTs (27)

XM 030577 Model mRNA:

XP 030577 Protein: Model

밆

뮵 Gen Bank Sequences

Ε

AB014511 AK025559

Mucleotide

Ε Ε

> AK026513 BC016044

阳

1	MTDSIPLQPV	RHKKRVDSRP	RAGCCEWLRC	CGGGEPRPRT	VWLGHPEKRD	QRYPRNVINN
61	QKYNFFTFLP	GVLFSQFRYF	FNFYFLLLAC	SQFVPEMRLG	ALYTYWVPLG	FVLAVTIIRE
					ILVEKNORVP	
181	KNGSCFLRTD	QLDGETDWKL	RLPVACTQRL	PTAADLLQIR	SYVYAEKPNI	DIHNFLGTFT
241	RENSDPPISE	SLSIENTLWA	GTVIASGTVV	GVVLYTGRKL	RSVMNTSDPR	SKIGLFDLEV
301	NCLTKILFGA	LVVVSLVMVA	LQHFAGRWYL	QIIRFLLLFS	NIIPISLRVN	LDMGKIVYSW
					MVFKRLHLGT	
421	VQSHIFSIYT	QQSQDPPAQK	GPTVTTKVRR	TMSSRVHEAV	KAIALCHNVT	PVYESNGVTD
481	QAEAEKQFED	SCRVYQASSP	DEVALVQWTE	SVGLTLVGRD	QSSMQLRTPG	DQVLNLTILQ
541	VFPFTYESKR	MGIIVRDEST	GEITFYMKGA	DVVMAGIVQY	NDWLEEECGN	MAREGLRVLV
601	VAKKSLTEEQ	YQHFEARYVQ	AKLSVHDRSL	KVATVIESLE	MEMELLCLTG	VEDQLQADVR
661	PTLETLRNAG	IKVWMLTGDK	LETATCTAKN	AHLVTRNQDI	HVFRLVTNRG	EAHLELNAFR
721	RKHDCALVIS	GDSLEVCLKY	YEYEFMELAC	QCPAVVCCRC	APTQKAQIVR	LLQERTGKLT
781	CAVWDGGNDV	SMIQESDCGV	GVEGKEGKQA	SLAADFSITQ	FKHLGRLLMV	HGRNSYKRSA
841	ALSQFVIHRS	LCISTMQAVF	SSVFYFASVP	LYQGFLIIGY	STIYTMFPVF	SLVLDKDVKS
901	EVAMLYPELY	KDLLKGRPLS	YKTFLIWVLI	SIYQGSTIMY	GALLLFESEF	VHIVAISFTS
961	LILTELLMVA	LTIQTWHWLM	TVAELLSLAC	YIASLVFLHE	FIDVYFIATL	SFLWKVSVIT
1021	L LVSCLPLYVI	KYLRRRESPI	SYSKLTS			

Figure 35

1	MTDNIPLQPV	RQKKRMDSRP	RAGCCEWLRC	CGGGEARPRT	VWLGHPEKRD	QRYPRNVINN
61	QKYNFFTFLP	GVLFNQFKYF	FNLYFLLLAC	SQFVPEMRLG	ALYTYWVPLG	FVLAVTVIRE
121	AVEEIRCYVR	DKEVNSQVYS	RLTARGTVKV	KSSNIQVGDL	IIVEKNQRVP	ADMIFLRTSE
					SYVYAEEPNI	
					RSVMNTSNPR	
301	NCLTKILFGA	LVVVSLVMVA	LQHFAGRWYL	QIIRFLLLFS	NIIPISLRVN	LDMGKIVYSW
					MIFKRLHLGT	
421	VQSHIFSIYT	QQSQDPPAQK	GPTLTTKVRR	TMSSRVHEAV	KAIALCHNVT	PVYESNGVTD
481	QAEAEKQYED	SCRVYQASSP	DEVALVQWTE	SVGLTLVGRD	QSSMQLRTPG	DOILNFTILO
541	IFPFTYESKR	MGIIVRDEST	GEITFYMKGA	DVVMAGIVQY	NDWLEEECGN	MAREGLRVLV
					MEMELLCLTG	
661	PTLETLRNAG	IKVWMLTGDK	LETATCTAKN	AHLVTRNQDI	HVFRLVTNRG	EAHLELNAFR
721	RKHDCALVIS	GDSLEVCLKY	YEYEFMELAC	QCPAVVCCRC	APTQKAQIVR	LLOERTGKLT
781	CAVGDGGNDV	SMIQESDCGV	GVEGKEGKQA	SLAADFSITO		HGRNSYKRSA
		LCISTMQAVF			STIYTMFPVF	
901	EVAMLYPELY	KDLLKGRPLS			GALLLFESEF	
					FIDVYFIATL	
		KYLERRESPP				

Figure 36

ATGACGGACAACATCCCGCTGCAGCCGGTGCGCCAGAAGAAGCGGATGGACAGCAGGCCC CGCGCCGGGTGCTGCGAGTGGCTGCGTGGAGGGGAGGCCAGGCCCGCACT GTCTGGCTGGGGCACCCCGAGAAGAGAGACCAGAGGTATCCTCGGAATGTCATCAACAAT CAGAAGTACAATTTCTTCACCTTTCTTCCTGGGGTGCTGTTCAACCAGTTCAAATACTTT TTCAACCTCTATTTCTTACTTCTTGCCTGCTCTCAGTTTGTTCCCGAAATGAGACTTGGT GCACTCTATACCTACTGGGTTCCCCTGGGCTTCGTGGTCGTCACTGTCATCCGTGAG GCGGTGGAGGAGATCCGATGCTACGTGCGGGACAAGGAAGTCAACTCCCAGGTCTACAGC CGGCTCACAGCACGAGGCACAGTGAAGGTGAAGAGTTCTAACATCCAAGTTGGAGACCTT ATCATCGTTGAAAAGAACCAGCGGGTCCCTGCCGACATGATCTTCCTGAGGACATCAGAA AAAAACGGGTCATGCTTCTTGCGGACGGATCAGCTGGATGGGAGACGGACTGGAAGCTG  ${\tt CGGCTTCCCGTGGCCTGCACGCAGAGGCTCCCCACGGCCGACCTTCTTCAGATTCGA}$ TCGTATGTGTACGCAGAAGAGCCAAATATTGACATTCACAACTTCGTGGGAACTTTTACC CGAGAAGACAGCGACCCCCGATCAGCGAGAGCCTGAGCATAGAGAACACGCTGTGGGCT GGCACTGTGGTCGCATCAGGTACTGTTGTGGGTGTTGTTCTTTACACTGGCAGAGAACTC CGGAGTGTCATGAATACCTCAAATCCCCGAAGTAAGATCGGCCTGTTCGACTTGGAAGTG AACTGCCTCACCAAGATCCTCTTTGGTGCCCTGGTGGTGGTCTCGCTGGTCATGGTTGCC CTTCAGCACTTTGCAGGCCGTTGGTACCTGCAGATCATCCGCTTCCTCCTCTTGTTTTCC AACATCATCCCCATTAGTTTGCGTGTGAACCTGGACATGGGCAAGATCGTGTACAGCTGG GTGATTCGAAGGGACTCGAAAATCCCCGGGACCGTGGTTCGCTCCAGCACGATTCCTGAG ATGATTTTCAAACGGCTCCATCTCGGAACAGTAGCCTACGGCCTCGACTCAATGGACGAA GTACAAAGCCACATTTTCAGCATTTACACCCAGCAATCCCAGGACCCACCGGCTCAGAAG GGCCCAACGCTCACCACTAAGGTCCGGCGGACCATGAGCAGCCGCGTGCACGAAGCCGTG AAGGCCATCGCGCTCTGCCACAACGTGACTCCCGTGTATGAGTCCAACGGTGTGACTGAT GATGAGGTGGCCCTGGTACAGTGGACGGAAAGTGTGGGCTTAACCCTGGTGGGCCGAGAC CAGTCTTCCATGCAGCTGAGGACCCCTGGCGACCAGATCCTGAACTTCACCATCCTACAG ATCTTCCCTTTCACCTATGAAAGCAAACGTATGGGCATCATCGTGCGGGATGAATCAACT AATGACTGGTTGGAGGAAGAGTGTGGCAACATGGCCCGAGAAGGGCTGCGGGTGCTCGTG GTGGCAAAGAAGTCTCTTGCAGAGGAGCAGTATCAGGACTTTGAAGCCCGCTACGTCCAG GCCAAGCTGAGTGTGCACGACCGCTCCCTCAAAGTGGCCACGGTGATCGAGAGCCTGGAG CCCACGCTGGAGACCCTGAGGAATGCTGGCATCAAGGTTTGGATGCTGACAGGGGACAAG CTGGAGACAGCTACGTGCACAGCGAAGAATGCACATCTGGTGACCAGAAACCAAGACATC CACGTTTTTCGGCTGGCCAACCGCGGGGAGGCTCACCTCGAGCTGAACGCCTTCCGC AGGAAGCATGATTGTGCCCTGGTCATCTCGGGAGACTCCCTGGAGGTTTGCCTCAAGTAC TATGAGTACGAGTTCATGGAGCTGGCCTGCCAGTGCCCGGCCGTAGTCTGCCGATGT GCCCCACCCAGAAGGCCCAGATCGTGCGCCTGCTTCAGGAGCGCACGGGCAAGCTCACC TGTGCAGTAGGGGACGGAGGCAATGACGTCAGCATGATTCAGGAATCTGACTGCGGCGTG GGAGTGGAAGGAAAGGAAAACAGGCTTCGTTGGCTGCAGACTTCTCCATCACTCAA TTTAAGCATCTTGGCCGGTTGCTTATGGTGCATGGCCGGAACAGCTACAAGCGGTCAGCC GCCCTCAGCCAGTTCGTGATTCACAGGAGCCTCTGTATCAGCACCATGCAGGCTGTCTTT TCCTCCGTGTTTTACTTTGCCTCCGTCCCTCTCTATCAAGGATTCCTCATCATTGGGTAC TCCACAATTTACACCATGTTTCCTGTGTTTTCTCTGGTCCTGGACAAAGATGTCAAATCG GAAGTTGCCATGCTGTATCCTGAGCTCTACAAGGATCTTCTCAAGGGACGGCCGTTGTCC TACAAGACATTCTTAATATGGGTTTTGATTAGCATCTATCAAGGGAGCACCATCATGTAC GGGGCGCTGCTGCTTTGAGTCGGAGTTCGTGCACATCGTGGCCATCTCCTTCACCTCG CTGATCCTCACCGAGCTGCTCATGGTGGCGCTGACCATCCAGACCTGGCACTGGCTCATG ACAGTGGCGGAGCTGCCTAGCCTGCTACATCGCCTCCCTGGTGTTCTTACACGAG TTCATCGATGTGTACTTCATCGCCACCTTGTCATTCTTGTGGAAAGTCTCCGTCATCACT CTGGTCAGCTGCCTCCCCCTCTATGTCCTCAAGTACCTGCGAAGACGGTTCTCTCCCCCC AGCTACTCAAAGCTCACATCA

Figure 37




Figure 38

score: 84 score: 88

Tetratricopeptide

repeats

score: 84

TPR Domain

Domains:

TPR Domain

NP 080272 RIKEN dDNA 2610100K07

7338 bps)										mRNA:	Protein:	Domains:			
Click to Display mRNA-Genomic Alignments (spanning 17338 bps)	10100K07 gene		duct, function	(07		TOM34 Mm Hs	TOM34 Mm Hs	TOMM34 Mm Hs		w	RefSeq			V CDNA BL	
mRNA-Genomic Alig	Mus musculus Official Gene Symbol and Name (MGI) 2610100K07Rik: RIKEN cDNA 2610100K07 gene	145 Submit: GeneRIF	gene with protein product, function unknown	RIKEN cDNA 2610100K07	λĥ	20q12- q13.1	20q12- q13.1	20q12- q13.1	The second secon	7	2	Seq).	ICTED	NP 080272 RIKEN CDNA	/0\00T0T0Z
Click to Display mRNA-Genomic	Mus musculus Official Gene Symbol and Name (MGI) 2610100K07Rik: RIKEN cDNA	LocusID: 67145 Qverview		Relationships	Maps:	NCBI vs. MGD	UCSC vs. MGD	NCBI vs. MGD	Map Information	Chromosome:	Cytogenetic:	NCBI Reference Sequences (RefSeq)	Category: PREDICTED	Protein:	

■ NCBI Reference Sequences (Refseq)	Category: PROVISIONAL	008900 WIN				Tetratricopeptide repeats score; 87	<b>~</b>			Category: NCBI Genome Annotation	Genomic NT 011362		Annotated transcripts/proteins for this locus:	Evidence: supported by	alignment with	DUD TIKKA BUD	ESTs (37)
NCBI Ref Sequence	Category	mRNA:	<b>Protein</b> :		Domains:		GenBank	source:		Category	Genomic	Contig:	Annotat	Evidence			
Homo saptens Official Gene Symbol and Name (HGNC)		membrane 34	LocusID: 10953	OVETVIEW TO THE PROPERTY OF TH	Proteome Summary: Subunit of the translocase of	ule outer mitodionarial membrahe; component of the mitochondrial protein import complex	Locus Type: gene with protein product function	_	. <b>Product:</b> translocase of outer mitochondrial	membrane 34	Alternate TOM34, HTOM34P	Symbols	Alias: outer mitochondrial membrane	Function Submit G-n & FTF	to F	11913975 Toman William Toman Jane 111	

score: 86 Tetratricopeptide score: 89 Domains: TPR Domain XP 029822 repeats

XM 029822

Model Protein:


Yeast two-hybrid screening identifies binding partners of human Tom34 that have ATPase activity and form a complex with Tom34 in the cytosol

mRNA: Model

mitochondrial precursor proteins with the leader sequences of

11913976

찚



MAPKLSDSVE ELRAAGNQSF YLKDGNCTDC IKDCTSALAL ALEGINRITR ALMDSLGPEW KSRVPSAGDV ERAKALKEEG KQYKEAVKDC TEALKLDGKN RQEVNONMN	NDLVKKGNHK	RASAYEALEK	YALAYVDYKT	VLQIDNSVAS
	NDLVKKGNHK	PVSAQKRWNS	LPSDNHKETA	KTKSKEATAT

### Figure 40

MAPKFPDSVEELRAAGNESFRNGQYAEASALYGRALRVLQAQGSSDPEEESVLYSNRAACHLKDGNCRDC IKDCTSALALVPFSIKPLLRRASAYEALEKYPMAYVDYKTVLQIDDNVTSAVEGINRMTRALMDSLGPEW RLKLPSIPLVPVSAQKRWNSLPSENHKEMAKSKSKETTATKNRVPSAGDVEKARVLKEEGNELVKKGNHK KAIEKYSESLLCSNLESATYSNRALCYLVLKQYTEAVKDCTEALKLDGKNVKAFYRRAQAHKALKDYKSS FADISNLLQIEPRNGPAQKLRQEVKQNLH

1	GGCACGAGGC	. ACCACACCC	CCACCAACCA	300300-0		
61	GGATGGCCCC	CAAATTCCCA	CACTCTCTC	AGGAGCTCCC AGGAGCTCCG	AACTCGCCGG	CCTGGCCACG
121	TCCGCAACGG	CCAGTACGCC	GACTCIGIGG	AGGAGCTCCG		AATGAGAGTT
181	AGGCGCAAGG	TTCTTCAGAC		CGCTCTACGG		
241		GGATGGAAAC		AAAGTGTTCT		
301		CAGCATTAAG		GCATCAAAGA	TTGCACTTCA	GCACTGGCCT
361		GGCCTATGTT		GGCGAGCATC	TGCTTATGAG	GCTCTGGAGA
421		AGGCATCAAC		CTGTGCTGCA		AATGTGACGT
481	GGCGCCTGAA	GCTGCCCTCA	AGAATGACCA	GAGCTCTCAT TGCCTGTTTC	GGACTCGCTT	GGGCCTGAGT
541	CCTTGCCTTC	GGAGAACCAC	ATCCCCTTGG	TGCCTGTTTC	AGCTCAGAAG	AGGTGGAATT
601	CAAAGAACAG	AGTGCCTTCT	GCTGGGGATG	CTAAAAGCAA	ATCCAAAGAA	ACCACAGCTA
661	GCAATGAGCT	TGTANAGANG	GCTGGGGATG	TGGAGAAAGC		
721			GGAAACCATA	AGAAAGCTAT		AGTGAAAGCC
781	TGAAGCAGTA	CACACAACCA	GTGAAGGACT	ACAGCAACAG	AGCACTCTGC	TATTTGGTCC
841	ACGTGAAGGC	ATTOTACA	GTGAAGGACT	GCACAGAAGC	CCTCAAGCTG	GATGGAAAGA
901	GCTTTGCAGA	CATCIACAGA	CGGGCTCAAG CTCCTACAGA		ACTCAAGGAC	TATAAATCCA
961	TGCGGCAGGA	ACTCAGCAAC	CTCCTACAGA	TTGAGCCTAG	GAATGGTCCT	
1021	CCTGACCTTA	CCCACACAAC	CCATGGGCCA	AAAAACCCAA		
1081	ATGCCCCANG	TGAGCTCTGA	CCATGGGCCA		${\tt GCCCGCTCCT}$	GAAACCCAGC
1141	GAGGCTTTGC	TTGTTCAAAT			GATGGCCTCC	CACCCTGTAA
	AGAAAGGTCC	CCACMACACA	TAAACTCAGT		ACAGACATGG	TTGTTGCACC
1261			TAAGCGTGAA		TGTCCCTATT	CCCCCAGCCC
1321	GTGGGCTGCA		AGATCCTCAT	CAGCAAAGCA	TTTGGCTTTG	TCCTGCCCAA
1381	ATCTGAACAA		TGCCCTTGTA	GCTTCCCCAG		ACTGCAGTTC
1441	ATCCAAAGCA		TGGGCCGGGG	TGGAAGGAGG	GGGATAAACC	TAAGGCCCTG
1501	CTGTCCCTGC		CTGGTTCTCC	AGGGCTGCAG	TCTCTCCAGG	TGTACAGCTG
1561	TTCGGGCCCT		CCTTGCACAG	TCTCCTATGT	CTGAGCCCCA	GTGCCTTCTG
1621	TGTGCTGCTG	CCTTTGGTGG	GAAGGCAGAG	CCCTGACCCT	TGAATGGTTG	TCCTTGACTC
1681			AGAGGCACCT	AAGCTGTTTA	AAGAGCCCAG	TGATTGTGGC
1741	GGCAGGGACT	AGAGGTGGGA		GGCCTCCTTG	GTCAGTGTCC	ATGCTTTCTG
1801	ATATCTTCAA	TGGTTTTTTG	TTCCAACAGT		GGGCTTCATA	GTTCTTTGTA
1861	ATATGTTGAA	GITAATTTGA		TTTGTTGAAC	TGTGTGTTTA	AGCTGTTGCA
1921	CCVCCACCVV	TTCTTCTACA	TCAATATCTG	CTGTGCTTTC	A CHIMMA MACACIM	
	AAAAAAAA	CICIGIAGIA	ATAATAAAAG	TTATTGCTTA	TTGGGCATTC	АААААААА
01	<b>STREET, STATE</b>					

Figure 42

MAPKFPDSVE ELRAAGNESF RNGQYAEASA LYGRALRVLQ AQGSS	DEFE CVI.VCNDAAC
HWKNGNCRDC IKDCTSALAL VPFSIKPLLR RASAYEALEK YPMAY	MANATURATION TO THE
AVEGINRMIR ALMOSLGPEW RLKLPSFPLV PVSAQKRWNF LPSEN	WYENN YCYCYRMWN W
KNRVPSAGDV EKARVLKEEG NELVKKGNHK KAIEKYSESL LCSNI	HOADY CHOALCULAT
KQYTEAVKDC TEALKLDGKN VKAFYRRAQA HKALKDYKSS FADIS	BESATI SNRALCYLVL
ROEVKONLH	NULQI EPRNGPAOKL

Figure 44




Figure 45





Figure 46



VISLPTKSRT CFSRKDKLKT SSQLTVHLRS KSHIRIKHSG RIHCTERPFK	SGSMQIPGGT AEETEPATQT KKPTAPPAQK HMRCHTGVKP HTGDAPFQCW NNFKCPHCDF CSYCSFDTKQ SFMREDSLRS	RLGCCYPGCQ YKCKTCDYAA LCSAKFKISS LGDSKSTLRK PSNLSKHMKK	FKTAYGMKDM ADSSSLNKHL DLKRHMRVHS HSRLHQSEHP	FEHGYQTYLP ERHLKIHTGD RIHSDERPFK GEKPFKCEFC EKCPECSYSC	TESTDNQTAT KPHKCEVCGK CQICPYASRN NVRCTMKGNL SSKAALRVHE
KILHCDICDA	SFMREDSLRS	HKRQHSEYHS	KNSDVTVVQL	HLEPSKOPLR	PSD

# Figure 47


# Figure 48

VIAPSTVQFV VISLPTKSRT CFSRKDKLKT SSQLTVHLRS YPGCHFKTVH CDYAAVDSSS FKISSDLKRH LEHSRLHQAD DKVHREGAKT	AEETEPATQT KKPTAPPAQK HMRCHTGVKP HTASVLENDV GMKDLDRHLR LKKHLRIHSD MIVHSGEKPF HPEKCPECSY ENRAPPGKDG	YKCKTCDYAA QKPAGLPAEE IHTGDKPHKC ERPYKCQLCP KCEFCDVRCT SCSNPAALRV PGESGPHHVP	TITVSAPEFV FKTAYGMKDM ADSSSLNKHL SDAQQAPAVT EFCDKCFSRK YASRNSSQLT MKANLKSHIR HSRVHCTDRP NVSTORAFGC	FEHGYQTYLP ERHLKIHTGD RIHSDERPFK LSLEAKERTA DNLTMHMRCH VHLRSHTGDT IKHTFKCLHC FKCDFCSFDT DKCGASFVPD	TLGERTFNCR TSVKPHKCHL PFQCWLCSAK AFQGRDRADL KPDSSLAVHT
SDWGENKNSN	PUNNAPAGENTA	PGESCIPHIVE	NVSTORAFGC	DKCGASEVED	DSLRCHRKQH

MNASVEGDTF VTAPSTVQFV VISLPTKSRT CFSRKDKLKT SSQLTVHLRS	KKPTAPPAQK HMRCHTGVKP	RLGCCYPGCQ YKCKTCDYAA	FKTAYGMKDM ADSSSLNKHI	FEHGYQTYLP	TESTDNQTAT
--	--------------------------	--------------------------	--------------------------	------------	------------

Figure 50

PCT/US2003/041613



MNASSEGESF	AGSVQIPGGT	TVLVELTPDI	HICGICKQQF	NNLDAFVAHK	OSGCOLTGTS
AAAPSTVQFV	SEETVPATOT	OTTTRTITSE	TOTTTVSAPE	FUFFIGVORV	T. DODGENTENTOO
WI ATSTINATO	KIKKPIIPPA	OKRLNCCYPG	COFKTAYCMK	DMEDULTION	CDEDITECTE
GKCFSRKDKL	KTHMRCHTGV	KPYKCKTCDY	AAADSSSLMK	HLRIHSDERP	GDIGHINCEVC
RNSSQLTVHL	RSHTGDAPFO	CWLCSAKEKT	SSDI-KDRMDA	HSGEKPFKCE	POWER
NLKSHIRIKH	SGNNFKCPHC	DELCDSKATI.	DESCRIPTION	HPEKCSECSY	FCNVRCTMKG
HERIHCTORP	FKCNYCSFDT	KUDGMI GKAM	MANAGORANA	EALERKDTGR	SCSSKAALRI
AKKSPHCDIC	DACEMBEDET	MOLDING MAIN	VVEHGDMAKT	EALERKDTGR	QSSRQVAKLD
OVDI-OPEOVE	OFCEODING	KSHKKQHSEY	NESKNSDVTV	LQFQIDPSKQ	PATPLTVGHL
OTT DOVICE TA	Or SEGKAKIT	VGHQVPQAN'I'	IVQAAAAAVN	IVPPALVAQN	PEELPGNSRL
QIURQVOUITA	PPQSSRCPSE	AGAMTQPAVL	LTTHEQTDGA	TLHQTLIPTA	SGGPQEGSGN
<b>GILIIDSGII</b>	CIDFEGUNAL	IQEGTAEVTV	VSDGGQNIAV	ATTAPPVFSS	SSQQELPKOT
X S T T Q GAAHP	ALLCPADSIP	D			

# Figure 51

MMACCECECE	ACCITOTOCCO			•	
MASSEGESF	AGS A OT LGGT.	TVLVELTPDI	HICGICKQQF	NNLDAFVAHK	OSGCOLTGTS
AWARDI.AĞE.A	SEETVPATOT	OTTTRTTTSE	TOTTTCCOFK	TAVEMEDMED	TIT TETTIMOTERS
HKCEVCGKCF	SRKDKT.KTHM	RCHTGVKPYK	CKECDAS	TATOMER	TIVITUIGNED
Tabua abuaa	ST. T. T	KCHIGAKPIK	CKTCDYAAAD	SSSLNKHLRI	HSDERPFKCO
TCPIASKNSS	CDIANTPREHL	GDAPFOCWLC	SAKFKTSSDL	KBHMBMHGGE	KDEACEECHL
RCTMKGNLKS	HIRIKHSONN	FKCPHCDFLG	DCKVUL DIGIG	TITIO CELEBRA	TO PRODUCE ON V
VANI DINEDI	***************************************	PRCENCDEDG	DSKATLKKHS	RVHQSEHPEK	CSECSYSCSS
VAADKIHEKI	HCIDKPFKCN	YCSFDTKQPS	NLSKHMKKFH	GDMVKTEALE	RKUTGBOSGB
QVAKLDAKKS	FHCDICDASF	MREDSLRSHK	BUHGEVGEGK	NGDUMUT ORO	TDDGWCD3-7
T.TVCHI.OVDI.	ODCOMBORGE	Chirman	KONDETERN	Manararded	TDPSKQPATP
HI A GUID OA EN	<b>GESOARGESE</b>	GRVKIIVGHQ	VPQANTIVQA	AAAAVNIVPP	ALVAONPEET.
PGNSKTÖTTK	GARPITAPBOR	SRCPSEAGAM	TOPAVITITIES	POTOGATE BO	TENTA COOR
OEGSGNOTET	TESCITTOTO	ECT MAT TORG		POIDGEITHO	THIPTASGGP
ZEGDONQIII.	TOSGITCIDE	EGLNALIQEG	TAEVIVVSDG	GQNIAVATTA	PPVFSSSSOO
FLFKQTYSII	QGAAHPALLC	PADSIPD			

ATVISLPAKS GKCFSRKDKL RNSSQLTVHL NLKSHIRIKH HERIHCTDRP AKKSFHCDIC QVPLQPSQVP QILRQVSLIA	RTKKPTTPPA KTHMRCHTGV RSHTGDAPFQ SGNNFKCPHC FKCNYCSFDT DASFMREDSL QFSEGRVKII PPQSSRCPSE	QTTTRTITSE QKRLNCCYPG KPYKCKTCDY CWLCSAKFKI DFLGDSKATL KQPSNLSKHM RSHKRQHSEY VGHQVPQANT AGAMTQPAVL	AAADSSSLNK SSDLKRHMRV RKHSRVHQSE KKFHGDMVKT SESKNSDVTV IVQAAAAAVN LTTHEQTDGA	FVFEHGYQTY DMERHLKIHT HLRIHSDERP HSGEKPFKCE HPEKCSECSY EALERKDTGR LQFQIDPSKQ IVPPALVAQN TLHQTLIPTA	LPTESNENQT GDKPHKCEVC FKCQICPYAS FCNVRCTMKG SCSSKAALRI QSSRQVAKLD PATPLTVGHL PEELPGNSRL SGGPOEGSGN
QTPITSSGIT	_	IQEGTAEVTV	VSDGGQNIAV	ATTAPPVFSS	SSQQELPKQT

Figure 53

80	
Ortholog identification module	5402
eQTL identification module	5404
cQTL identification module	5406
Determination module	5408
Classification module	
•	5410
•	







Fig. 5.





49/91








51/91






















# Human Association Analysis

Given a gene identified in mouse for EZE response, we can directly test whether polymorphisms in this gene in human populations are associated with this trait



Ex: Is the frequency of the polymorphism equal between EZE responders and non-responders?

41g. 67






Fig. 69





Fig. 70

7102 Select a trait, optionally expose a portion of a plurality of organisms to a perturbation that affects the trait 7104 Measure gene expression / cellular constituent level data 50 in the secondary tissue of a plurality of organisms 46 7106 Transform gene expression / cellular constituent level data 50 into expression statistics 7150 Measure one or more phenotypes for all or a portion of the organisms 46 in the plurality of organisms 7152 Classify the plurality of organisms into distinct phenotypic groups based on the phenotypes exhibited by the organisms 7154 Identify the phenotypic extremes for the subpopulation with respect to the trait under study or a phenotype related to the trait under study 7156 Filter the cellular constituent data to identify which cellular constituents discriminate the organisms into the phenotypic extremes identified in step 7154 (e.g., application of a t-test) 7158 Optionally, reduce the number of cellular constituents from step 7156 using a reducing algorithm (e.g., stepwise regression, principal component analysis, a stochasitc search, etc.) 7160 Optionally, cluster (e.g., k-means clustering) cellular constituents from step 7158 (or step 7156) to identify further subgroups within each phenotypic subpopulation 7164, Fig. 71B **FIG.** 71A



**FIG. 71B** 

	Phenotype 1		Phenotype M	CC 48-1	•••	CC 48-Z
Organism 46-1	Amount 7201-1-1	• • •	Amount 7201-1-M	Level 50-1-1	• • •	Level 50-1-Z
Organism 46-2	Amount 7201-2-1	• • •	Amount 7201-2-M	Level 50-2-1	• • •	Level 50-2-Z
•	•	• • •	•	•	• • •	:
Organism <sup>-</sup> 46-N	Amount 7201-N-1	• • •	Amount 7201-N-M	Level 50-N-1	•••	Level 50-N-Z

FIG. 72




FIG. 73




Fig. 74





Fig. 75A

Genotype BB

Figure 75B






Figure 75C





Figure 75D






Fig. 76




Fig. 77




Fig. 78

-7902

Genotype a population under study and, optionally, use pedigree information for the population

7904

Phenotype the population with respect to a trait or traits of interest and map quantitative trait loci (cQTL) for each phenotype, resulting in a set of cQTL linked to the trait

7906

Obtain abundance data for a plurality of cellular constituents from one or more tissues in each member of the population under study

7908

Identify cellular constituents (association set **D**) whose abundance levels accross the population significantly associate with the trait of interest (e.g., by use of Pearson correlations, basic discriminant analysis, regression models, etc.)


7910

For each cellular constituent i in association set **D**, perform quantitative genetic analysis, in which abundance levels of cellular constituent i across the population serve as a quantitative trait, in order to identify eQTL for cellular constituent i

7912

Remove all cellular constituents from association set **D** that do not have at least one eQTL that is coincident with (within a support interval of) a cQTL for the trait of interest in order to form the candidate causative cellular constituent set. Optionally, require that all coincident eQTL/cQTL pass a pleiotropy test in order to be considered coincident. Cellular constituents removed from association set **D** form a candidate reactive cellular constituent set.

7914



- 7916

For each cellular constituent i in the candidate causative cellular constituent set, determine the amount of genetic variation in the trait of interest that is explained by the eQTL of cellular constituent i coincident with the cQTL from the trait of interest. Rank order the cellular constituents in the candidate causative cellular constituent set based upon the amount of genetic variation in the trait of interest that is explained by each cellular constituent determined in this manner.

- 7918

For each eQTL of each cellular constituent i in the candidate causative cellular constituent set, test for the relationship:

$$P(T,Q|G) = P(T|G)P(Q|G)$$

where,

T is variance in the trait of interest,

Q is variance in the genome at the position where the eQTL (assoicated with cellular constituent i) overlaps with a cQTL linked to the trait of interest, and

G is variance in the abundance level of cellular constituent i

7920

Optionally, determine whether each cellular constituent i in the candidate causative cellular constituent set includes a druggable domain


7922

Optionally, rank cellular constituents in the candidate causative cellular constituent set based on the rank assigned in step 716 and the results of step 7918 and/or step 7920

7924

Optionally, validate top ranking cellular constituents using gene knock outs/ins, transgenic construction, siRNA, drug treatments targeting candidate genes, time series experiments, etc.

		_
Ph	enotypic statistic set for clinical trait 1	8000-1
	Phenotypic value for organism 1	8004-1-1
	Phenotypic value for organism 2	8004-1-2
i	Phenotypic value for organism 3	8004-1-3
	•	- 0004-1-0
	Phenotypic value for organism Q	8004-1-Q
	•	]
Ph	enotypic statistic set for clinical trait Z	8000-Z
	Phenotypic value for organism 1	8004-Z-1
	Phenotypic value for organism 2	8004-Z-2
	Phenotypic value for organism 3	8004-Z-3
	•	000+2-0
	Phenotypic value for organism Q	8004-Z-Q
	•	_



**FIG. 81** 

8104- <b>G</b>	
Abundance statistic for gene <b>G</b> from organism 1	8108- <b>G</b> -1
Abundance statistic for gene <b>G</b> from organism 2	8108- <b>G</b> -2
Abundance statistic for gene <b>G</b> from organism 3	8108- <b>G</b> -3
Abundance statistic for gene <b>G</b> from organism 4	8108- <b>G</b> -4
•	0100-0-4
Abundance statistic for gene <b>G</b> from organism N	8108- <b>G</b> -N






FIG. 83

Abundance statistic set	L 04044
	. 8104-1
Position 1	8404-1-1
Statistical score	8406-1-1
Position 2	8404-1-2 8406-1-2
Statistical score	
Position X	8404-1-X
Statistical score	~- 8406-1-X
Abundance statistic set	8104-M 18404-M-1
Position 1	
Statistical score	~8406-M-1
Position 2	8404-M-2
Statistical score	8406-M-2
	3 . <b>3</b>
Position X	8404-M-X
Statistical score	8406-M-X





**FIG. 85A** 



**FIG. 85B** 







## Lod Score Curve for INS Chromosome 13 QTL






Fig. 86A


### Lod Score Curve for EPIPA Chromosome 13 QTL




### Lod Score Curve for LEP Chromosome 13 QTL




### Lod Score Curve for CHDL Chromosome 13 QTL






1 mdvvdsllvn gsnitppcel glenetlfcl dqprpskewq pavqillysl ifllsvlgnt
61 lvitvlirnk rmrtvtnifl lslavsdlml clfcmpfnli pnllkdfifg savcktttyf
121 mgtsvsvstf nlvaislery gaickplqsr vwqtkshalk viaatwclsf timtpypiys
181 nlvpftknnn qtanmcrfll pndvmqqswh tflllilfli pgivmmvayg lislelyqgi
241 kfeasqkksa kerkpsttss gkyedsdgcy lqktrpprkl elrqlstgss sranrirsns
301 saanlmakkr virmlivivv lfflcwmpif sanawraydt asaerrlsgt pisfilllsy
361 tsscvnpiiy cfmnkrfrlg fmatfpccpn pgppgargev geeeeggttg aslsrfsysh
421 msasvppq (SEQ ID NO: 30)

Fig. 88





# CCKAR haplotypes associate with high body fat in females

Percentage body fat (top 15%) females

	ł		1	
Info	0.81	0.75		-
E Z	282	279		9002
Ctrl fra	0.03	0.03		J
Naff	281	281		
Aff_frq	0.11	0,11		
PAR	0.163	0.163		
RRisk	4.0	4.2		
P-unc	8.42E-07	1.43E-06		
P CO	0.002	0.002		

23% obese vs 6% thin and Relative Risk >4 Carrier frequency:

Controls: Thin females

Fig. 90



## CCKAR haplotypes associate with thinness in females

Thin (BMI<20) females at ages > 40 yrs

. cor P-unc RRisk PAR Aff frq N aff Ctrl frq N ctrl Info 0.02 1.61E-05 4.4 0.119 0.08 282 0.02 421 0.643 0.02 1.84E-05 4.2 0.120 0.08 282 0.02 421 0.647

17% thin vs 4% obese and Relative Risk >4 Carrier frequency:

Fig. 91

Controls: Obese females